Vera Bril Selected Research

ranirestat

12/2015	Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
7/2009	Ranirestat for the management of diabetic sensorimotor polyneuropathy.
7/2008	Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
7/2008	Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
1/2006	Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
10/2004	Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vera Bril Research Topics

Disease

43	Polyneuropathies (Polyneuropathy) 01/2022 - 04/2004
34	Myasthenia Gravis 06/2022 - 11/2003
30	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2022 - 02/2008
14	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 01/2012
10	Pain (Aches) 01/2022 - 12/2002
10	Diabetic Neuropathies (Diabetic Neuropathy) 01/2019 - 03/2002
9	Peripheral Nervous System Diseases (PNS Diseases) 06/2022 - 08/2005
5	Paraproteinemias (Monoclonal Gammopathy) 01/2021 - 01/2016
5	Guillain-Barre Syndrome 11/2017 - 04/2007
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 06/2014
3	Neuralgia (Stump Neuralgia) 07/2021 - 01/2016
3	Headache (Headaches) 01/2021 - 09/2010
2	COVID-19 11/2022 - 01/2021
2	Hypesthesia (Numbness) 06/2022 - 08/2005
2	Cardiomyopathies (Cardiomyopathy) 06/2022 - 01/2021
2	Amyloidosis 01/2022 - 01/2021
2	Wounds and Injuries (Trauma) 07/2021 - 01/2016
2	Thymoma (Thymic Carcinoma) 01/2021 - 11/2002
2	Motor Neuron Disease (Primary Lateral Sclerosis) 11/2019 - 04/2007
2	Fatigue 08/2018 - 05/2013
2	Anemia 01/2018 - 01/2016
2	Hypertension (High Blood Pressure) 01/2016 - 01/2015
2	Monoclonal Gammopathy of Undetermined Significance 09/2015 - 12/2014
2	Polymyositis 07/2015 - 04/2007
2	Diabetes Mellitus 08/2005 - 08/2005
2	Carpal Tunnel Syndrome 03/2004 - 03/2002
1	Transthyretin-Related Hereditary Amyloidosis 06/2022
1	Weight Loss (Weight Reduction) 06/2022
1	Meningococcal Meningitis 06/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Fasciculation (Fasciculations) 01/2021
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 07/2020

Drug/Important Bio-Agent (IBA)

31	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 03/2007
16	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 02/2012
10	HizentraIBA 01/2022 - 01/2016
7	Cholinergic ReceptorsIBA 05/2022 - 06/2012
7	NAD (NADH)IBA 01/2021 - 03/2002
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2012
6	CaprylatesIBA 01/2019 - 02/2008
6	ranirestatIBA 12/2015 - 10/2004
5	AntibodiesIBA 05/2022 - 06/2012
5	SteroidsIBA 07/2021 - 01/2016
5	Aldehyde Reductase (Aldose Reductase)IBA 07/2009 - 10/2004
4	Immunoglobulin G (IgG)IBA 01/2021 - 01/2018
4	Uric Acid (Urate)IBA 01/2019 - 01/2016
4	Immunoglobulin M (IgM)IBA 09/2015 - 04/2007
4	Sorbitol (Yal)FDA Link 07/2008 - 05/2004
3	Prealbumin (Transthyretin)IBA 06/2022 - 01/2021
3	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2018
3	glucose-mannose-glucoseIBA 05/2022 - 01/2019
3	AutoantibodiesIBA 01/2021 - 01/2019
3	Antidepressive Agents (Antidepressants)IBA 01/2021 - 04/2011
3	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021 - 04/2011
3	Creatine Kinase (Creatine Phosphokinase)IBA 12/2019 - 01/2016
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 01/2016
3	Opioid Analgesics (Opioids)IBA 01/2019 - 04/2011
2	Biological ProductsIBA 06/2022 - 07/2020
2	Complement Inactivating AgentsIBA 06/2022 - 12/2019
2	Sodium Channel BlockersIBA 01/2022 - 01/2021
2	Analgesics (Analgesic Drugs)IBA 07/2021 - 05/2013
2	neonatal Fc receptorIBA 01/2021 - 01/2019
2	Immunoglobulin Fc FragmentsIBA 01/2021 - 01/2019
2	Monoclonal AntibodiesIBA 01/2021 - 01/2018
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021 - 06/2017
2	Retinaldehyde (Retinal)IBA 01/2019 - 10/2011
2	Hemoglobins (Hemoglobin)IBA 01/2018 - 11/2013
2	Insulin (Novolin)FDA Link 01/2018 - 01/2016
2	CholesterolIBA 01/2016 - 08/2006
2	IceIBA 09/2010 - 02/2008
1	VaccinesIBA 11/2022
1	Serotonin and Noradrenaline Reuptake InhibitorsIBA 01/2022
1	Local AnestheticsIBA 07/2021
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2021
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2021
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2021
1	Nortriptyline (Aventyl)FDA LinkGeneric 01/2021
1	Mexiletine (Mexitil)FDA LinkGeneric 01/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 01/2021
1	Pregabalin (Lyrica)FDA Link 01/2021
1	eculizumab FDA Link 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	rozanolixizumabIBA 01/2021
1	Myelin-Associated GlycoproteinIBA 01/2021

Therapy/Procedure

25	Therapeutics 06/2022 - 04/2004
8	Glycemic Control 01/2022 - 12/2002
6	Activities of Daily Living (ADL) 01/2021 - 07/2016
6	Plasma Exchange 11/2019 - 03/2008
5	Immunomodulation 01/2021 - 08/2005
4	Thymectomy 01/2021 - 11/2002
4	Aftercare (After-Treatment) 08/2018 - 03/2004
4	Lasers (Laser) 01/2014 - 04/2011
3	Immunotherapy 01/2022 - 01/2008
2	Nutrition Therapy (Medical Nutrition Therapy) 01/2022 - 01/2021
2	Analgesia 01/2016 - 05/2012
2	Plasmapheresis 01/2013 - 05/2012
2	Massage (Zone Therapy) 06/2011 - 04/2011
2	Therapeutic Touch (Reiki) 06/2011 - 04/2011
1	Drug Therapy (Chemotherapy) 06/2022
1	Injections 07/2021